Nov 27, 2012 by Brian Orelli, PhDThird Time's the CharmAcadia tweaks its clinical trial design to show an effect for pimavanserin in Parkinson’s disease psychosis
Nov 26, 2012 by Brian Orelli, PhDWhat's Taking So Long to Approve This Drug?Investors should be a little worried that Exelixis' cancer drug cabozantinib hasn't gained FDA approval yet.
Nov 26, 2012 by Brian Orelli, PhDKnow Your Management Team: Abbott LabsWho's behind the wheel at Abbott and AbbVie.
Nov 21, 2012 by Brian Orelli, PhD1 Risk You Must Understand With This SpinoffAll Humira, All The Time
Nov 20, 2012 by Brian Orelli, PhDPainful! Pfizer's Batting .500Extended release versions of approved drugs are supposed to be low risk.
Nov 19, 2012 by Brian Orelli, PhDIs This Biotech Fishing for a Higher Bid?Geron announces that its selling its stem cell assets, but the deal isn't finalized yet.
Nov 19, 2012 by Brian Orelli, PhDDoes VIVUS Have the Right Management Team?A look at this drugmaker's executive team.
Nov 16, 2012 by Brian Orelli, PhDSafety Matters (to a Point)Dynavax in the wake of FDA committee decision on safety data.
Nov 16, 2012 by Brian Orelli, PhDWhat Are the Biggest Risks Facing VIVUS Today?VIVUS may have gained FDA approval for Qsymia, but what must it do now to succeed?
Nov 15, 2012 by Brian Orelli, PhD3 Biotechs Burning Cash to Keep the Lights OnSurviving to profitability is the name of the game.
Nov 15, 2012 by Brian Orelli, PhDAre Arena and VIVUS Frenemies?Growing the obesity drug market together.
Nov 13, 2012 by Brian Orelli, PhDPartner! Oh, Wait, Never Mind.MannKind gets a partner, just not for its lead product Afrezza.
Nov 13, 2012 by Brian Orelli, PhDAreas That VIVUS Investors Must WatchWhat are the important issues facing this biotech stock today?
Nov 13, 2012 by Brian Orelli, PhDBuyout or Burnout for Amarin?Amarin needs a partner sooner rather than later.
Nov 13, 2012 by Brian Orelli, PhD3 Reasons Why Not All Hep C Data Is Created EqualGilead's hepatitis C data beat Abbott's, but there are caveats.
Nov 12, 2012 by Brian Orelli, PhD2 Risks Facing Merck TodayIs this pharma stalwart navigating through choppy waters?
